Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Bone or Joint Infection
Interventions
DRUG

Afabicin

Administered intravenously and orally.

DRUG

Standard of Care

Administered with SOC in accordance with local practice and applicable treatment guidelines.

Trial Locations (19)

1500

Worthwhile Clinical Trials, Lakeview Hospital, Benoni

4600

West Georgia Medical Center LLC, Kutaisi

21028

Vinnytsya Regional Clinical Hospital, Vinnytsia

49027

Dnipropetrovsk Regional Clinical Hospital, Dnipro

61176

Kharkiv Regional Clinical Traumatology Hospital, Kharkiv

69065

City Hospital #9 under Zaporizhia City Council, Zaporizhia

76008

Regional Clinical Hospital under Ivano-Frankivsk Regional Council, Ivano-Frankivsk

79495

Lviv Regional Hospital of Veterans of Wars and Repressed after Yurii Lypa, Vynnyky

0800

Georgian Clinics JSC, Akhalts'ikhe

0101

Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC, Tbilisi

0141

LEPL The First University Clinic of Tbilisi State Medical University, Tbilisi

0144

Tbilisi State Medical University And Ingorokva High Medical Technology University Clinic LLC, Tbilisi

0160

Academician Vakhtang Bochorishvili Clinic LTD, Tbilisi

0186

Caucasus Medical Center LLC, Tbilisi

0002

Clinical Research Unit, University of Pretoria, Pretoria

0157

Global Clinical Trials (Pty) Ltd, Pretoria

01601

Institute of Traumatology and Orthopedics, Kyiv

04107

Kyiv Regional Clinical Hospital, Kyiv

Unknown

Kyiv City Clinical Hospital #8 under the Executive Body of Kyiv City Council (Kyiv City State Administration), Kyiv

Sponsors
All Listed Sponsors
lead

Debiopharm International SA

INDUSTRY